Publicacións en colaboración con investigadores/as de Universidade de Santiago de Compostela (35)

2024

  1. Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 421-433

2023

  1. Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly

    Clinical Endocrinology, Vol. 99, Núm. 4, pp. 378-385

2022

  1. Data mining analyses for precision medicine in acromegaly: a proof of concept

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas

    Clinical Endocrinology, Vol. 94, Núm. 5, pp. 811-819

  2. Pasireotide in the Personalized Treatment of Acromegaly

    Frontiers in Endocrinology, Vol. 12

2020

  1. Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey

    Pituitary, Vol. 23, Núm. 2, pp. 129-139

  2. Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

    Endocrine, Vol. 70, Núm. 3, pp. 575-583

  3. GFRα 1-2-3-4 co-receptors for RET Are co-expressed in Pituitary Stem Cells but Individually Retained in Some Adenopituitary Cells

    Frontiers in Endocrinology, Vol. 11

  4. Molecular profiling for acromegaly treatment: a validation study

    Endocrine-related cancer, Vol. 27, Núm. 6, pp. 375-389

2019

  1. Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegaly

    EBioMedicine, Vol. 43, pp. 537-552

2018

  1. Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus

    Endocrinologia, Diabetes y Nutricion, Vol. 65, Núm. 5, pp. 297-305

  2. Expert document on management of acromegaly

    Endocrinologia, Diabetes y Nutricion, Vol. 65, Núm. 8, pp. 428-437

2017

  1. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement

    Pituitary, Vol. 20, Núm. 5, pp. 489-498

  2. Long-term outcome of multimodal therapy for giant prolactinomas

    Endocrine, Vol. 55, Núm. 1, pp. 231-238

  3. Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer

    Oncogene, Vol. 36, Núm. 5, pp. 652-666

2016

  1. Long-term treatment with pegvisomant for acromegaly: A 10-year experience

    Clinical Endocrinology, Vol. 84, Núm. 4, pp. 540-550

2015

  1. Hypopituitarism After Traumatic Brain Injury

    Endocrinology and Metabolism Clinics of North America, Vol. 44, Núm. 1, pp. 151-159

  2. Update on prognostic factors in acromegaly: Is a risk score possible?

    Pituitary, Vol. 18, Núm. 3, pp. 431-440

2014

  1. Cabergoline treatment in acromegaly: Pros

    Endocrine, Vol. 46, Núm. 2, pp. 215-219

  2. Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNF

    Endocrinology, Vol. 155, Núm. 11, pp. 4329-4340